Skip to main content
. 2015 Jun 26;172(15):3875–3889. doi: 10.1111/bph.13177

Figure 3.

Figure 3

LCB54-0009 inhibits corneal neovascularization and inflammation-associated lymphangiogenesis. (A–E) Proliferation of blood vessels (BV) and lymphatic vessels (LV) were generated in the SICNV mouse model (n = 5 per group). Vehicle (0.1% DMSO), LCB54-0009 (100 μg) or VEGF trap (100 μg) was injected subconjunctivally on the day of corneal suture placement. Corneal angiogenesis, lymphangiogenesis and inflammation were determined by staining with CD31 (red), LYVE-1 (green) and CD11b (blue) antibodies respectively (A). BV diameter (B), BV density (C), LV density (D) and the infiltration area of inflammatory cells (E) were measured. Scale bars = 500 μm. (F and G) Corneal neovascularization was induced by the subconjunctival injection of silver nitrate to cauterize the cornea of rats (n = 5 per group). Vehicle (1% DMSO), LCB54-0009 (50 μg) or Avastin (200 μg) was injected subconjunctivally three days after silver nitrate cauterization and measured using an ophthalmic microscope with a digital camera. Original magnification was ×100. Avastin was used as a positive control. *P < 0.05 and **P < 0.005 versus control mice. CTL, control; LCB54, LCB54-0009; V-trap, VEGF trap.